# Ventricular Tachycardia: Catheter Ablation Four Questions: Who? When? How? Results?

Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital

vivek.reddy@mountsinai.org





# Disclosures

- Grant support and/or Consultant:
  - Abbott & Biosense-Webster

• I will be discussing off-label use of catheter ablation devices.





# Outline

- Scar-Related VT Ablation
- Outflow-Tract VT/PVCs
- Ventricular Fibrillation





# Outline


- Scar-Related VT Ablation
- Outflow-Tract VT/PVCs
- Ventricular Fibrillation






## Pathogenesis of Scar-Related VT

## **Myocardial Fibrils Traversing Through Fibrotic Tissue**






# Substrate Mapping & Ablation








# Substrate Mapping & Ablation






#### 3. Homogenize Scar






# **Image-Guided VT Ablation?**

## **MRI-Guided Single-Center Experience**








MOUNT SINAL SCHOOL OF MEDICINE

#### Multicenter Thermocool VT Ablation IDE Trial

### **Long-Term Outcomes**










## VANISH: Post-MI VT

#### RCT: AADs vs Catheter Ablation









# Primary Prevention of ICD Shocks SMASH-VT

Preventative substrate ablation in preventing ICD shocks in post-MI pts who have sustained a VT/VF event (ie,  $2^{\circ}$  prevention ICD pts)










Reddy et al, *NEJM*, 357:2657 (2007)

# Primary Prevention of ICD Shocks VTACH Study

Can catheter ablation reduce VT/VF in post-MI patients undergoing ICD implantation for stable VT?
















## **Catheter Ablation in DCM-VT**

## **Moderate Success (Compared to Post-MIVT)**



21


200

33

MEDICINE

For DCM-VT, the only predictors of VT recurrence were "Partial Success" or Failure.

	-			
	NIDCM, HR; 95% CI	<i>P</i> Value	ICM, HR; 95% CI	<i>P</i> Value
Age	0.98; 0.95–1.015	0.278	0.97; 0.95-0.99	0.038
Diabetes mellitus			1.3; 0.77-2.24	0.313
Heart failure, NYHA class I-IV	1.02; 0.63-1.66	0.929	1.36; 1.02–1.81	0.034
EF, %	1.003; 0.97–1.03	0.853	0.98; 0.96-1.007	0.172
Failure vs complete success	4.12; 1.56–10.89	0.004	4.48; 1.2-16.65	0.025
Partial vs complete success	3.28; 1.25–8.65	0.016	1.9; 1.004–3.58	0.048
No. of VTs	1.13; 0.83–1.53	0.443	1.2; 0.98-1.47	0.076
Epicardial ablation	1.86; 0.76-4.53	0.172		
$\beta$ -Blocker	2.04; 0.63-6.62	0.236	1.02; 0.24-4.3	0.975
AAM	0.48; 0.22-1.07	0.072	1.71; 0.94-3.1	0.079






Dinov B et al. *Circulation* 129:728-36 (2014)

## **Catheter Ablation in DCM-VT**

## **Improved Success with Scar Homogenization (?)**









# **Image-Guided DCM-VT Ablation**

### **MRI-Guided Single-Center Experience**










- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??




Bogun at al, *JACC* 53:1138-45 (2009)





- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??











- Deep (Septal) Circuits
  - Hemodynamic Support
  - **EtOH Ablation**
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??








# The Difficult VT Ablation Can we improve outcomes?

- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??




# Mostly Intramural Scar: What can you do?





# The Difficult VT Ablation Can we improve outcomes?

- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??








- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??











Can we improve outcomes?


- Deep (Septal) Circuits
  - Hemodynamic Support
  - **EtOH** Ablation
  - Bipolar RF
  - Needle Ablation
- **Epicardial Ablation**
- Radiotherapy??






**ARVC-VT** 


AP Burke, Medscape, http://emedicine.medscape.com /article/1612324-overview HCM-VT








- Deep (Septal) Circuits
  - Hemodynamic Support
  - EtOH Ablation
  - Bipolar RF
  - Needle Ablation
- Epicardial Ablation
- Radiotherapy??












# Transplant/Mortality After VT Ablation

#### Outcome as a Function of Ablation Success

#### Predictors of Transplant/Mortality



P	Hazard Ratio (95% CI)	Transplant/Mortality	Effect
			Patient Characteristics
0.214	0.685 (0.376 - 1.245)	<b>⊢</b> ♦†I	ICD-
< 0.00	0.858 (0.796 - 0.925)	<b>₩</b> ¦	EF Pre-Ablation (+5%)-
0.464	0.878 (0.620 - 1.244)	H <b>♦</b> H	Beta-Blocker-
0.994	0.999 (0.753 - 1.325)	H∳H	Ischemic Cardiomyopathy-
0.843	1.028 (0.782 - 1.352)	H∳H	Atrial Fibrillation-
0.737	1.057 (0.767 - 1.456)	+++	Amiodarone-
0.708	1.062 (0.774 - 1.458)	+++	≥ 2 AAD-
0.048	1.066 (1.001 - 1.136)	*	Age (+5y)-
0.573	1.104 (0.782 - 1.559)	H <del>.</del> ♦-I	ICD Shocks-
0.126	1.112 (0.971 - 1.273)	<b>(</b> ♦)	Prior VT Ablations (+1)-
0.386	1.187 (0.806 - 1.747)	H∳H	Female-
0.188	1.204 (0.913 - 1.587)	H∳H	CRT-
0.027	1.369 (1.036 - 1.809)	<b>i</b> ++1	Diabetes Mellitus-
0.009	1.438 (1.094 - 1.891)	i⊦◆⊦	Chronic Kidney Disease-
0.004	1.499 (1.135 - 1.980)	H♦H	Electrical Storm-
0.108	1.506 (0.914 - 2.479)	i <del>-</del>	NYHA: II v. I-
0.001	2.308 (1.403 - 3.798)	i +++	NYHA: III v. I-
< 0.00	3.681 (2.004 - 6.760)	·	NYHA: IV v. I-
			Procedural Characteristics
0.461	0.767 (0.379 - 1.552)	<b>⊢</b> ♦ <del> </del>	Ablation: Epi v. Endo-
0.825	0.959 (0.665 - 1.385)	<b>⊢</b> ♦⊣	Ablation: Endo + Epi v. Endo-
0.697	0.996 (0.975 - 1.017)	<b>+</b>	Procedure Time (+15m)-
0.416	1.285 (0.703 - 2.350)	<b>⊢</b> ¦♦─1	VTs Induced: 1 v. 0-
0.107	1.625 (0.900 - 2.935)	1 →	VTs Induced: 2 v. 0-
0.157	1.522 (0.851 - 2.721)	+ + -	VTs Induced: ≥ 3 v. 0-
0.246	1.298 (0.836 - 2.015)	H <del>↓</del> ◆	Procedural Complications
<0.00	2.128 (1.415 - 3.199)	; H+H	Hemodynamic Support Device-
- 1000-100			Outcomes
0.004	1.972 (1.248 - 3.116)	! ⊢◆⊣	Acute: Not Tested v. NI-
<0.00	1.994 (1.480 - 2.687)	! +◆+	Acute: Partial/Failure v. NI-
<0.00	6.901 (5.282 - 9.017)	! ⊩+⊢	VT Recurrence-











# Transplant/Mortality After VT Ablation

## **Outcome: Relationship to Functional Class**
















# Mortality After VT Ablation

## **Effect of Acute Inducibility: Mortality**

- 102 consecutive pts undergoing scar-VT ablation
- 817 patients with ICDs and a history of appropriate shocks
- 2,088 patients with ICDs and no history of appropriate shocks











Bunch et al, *Heart Rhythm* 11:523 (2014)

# Outline


- Scar-Related VT Ablation
- Outflow-Tract VT/PVCs
- Ventricular Fibrillation







## **Outflow-Tract VT**

- Structurally-normal heart
- RVOT- or LVOT-VT
- ECG:
  - Typically LBBB (or RBBB)
  - Positive QRS in II / III / aVF
  - QRS transition V3/V4
    - Early transition → LVOT
    - Can be RBBB
- Not life-threatening
  - [rare exceptions]





# **RVOT VT Ablation**









## **Ablation of Outflow-Tract VT/PVC**

## LVOT / Ao Cusps / Distal GCV / LV / LAA








MOUNT SINAL SCHOOL OF MEDICINE

# What about PVCs?

## Canine Model: Bigeminal PVC Pacing vs Control








## **Effect of PVC Ablation**

## **Prospective 4-Center Study (n=80 pts)**

- <u>13% baseline PVC burden</u>: 100% Sens / 85% Specificity to predict an absolute LVEF increase of 5% after catheter ablation
- 20 patients with Class I ICD indication no longer eligible at 6 months post-ablation.











# **CRT Non-Responders Effect of PVC Ablation**

- 65 CRT Non-Responders with >10,000 PVCs/24h undergoing ablation
- Age 66.6, 78% male, QRS duration =  $155 \pm 18$  msec
- Acute and 12-mo success of ablation: 91% and 88%
- Improvements in LVEF (26.2 → 32.7%, p 0.001)
  - LVESD, LVEDD, LVESV, LVEDV, NYHA (3.0 to 2.0, p 0.001)











# **Predictors of PVC-Cardiomyopathy**


## **Interpolated PVCs**

#### **Interpolated PVCs**

Higher risk for Cardiomyopathy

#### Symptoms

– Asymptomatic: HR = 13



#### **QRS Width**

- QRS >150ms best predictive
- Sens = 80% / Spec = 52%







V1


# Other Types of PVCs


## **Papillary-Muscle PVCs**
















MEDICINE



# Should all PVC patients undergo MR Imaging?

Single-Center Experience



SCHOOL OF

MEDICINE

SCHOOL OF

MEDICINE


# Outline

- Scar-Related VT Ablation
- Outflow-Tract VT/PVCs
- Ventricular Fibrillation







# Ventricular Fibrillation Focal Triggers



RVOT muscle
16%










## **VF Triggers in Other Disease States**

## **Channelopathy & Post-MI**





#### **Post-MI**




Haissaguerre et al, Circ 108:925 (2003) Bansch et al, Circ 108:3011 (2003) S.Dukkipati / V.Reddy, *J Am Coll Cardiol* 70:2909-23 (2017)



MOUNT SINAL SCHOOL OF MEDICINE

## VF Substrate Mapping in Brugada Syndrome

Normal and Abnormal Epicardial Electrograms








## Brugada Syndrome: VF Substrate Ablation

**ECG Pattern During Follow-Up** 







# Final Thoughts

- Scar-Related VT:
  - Ablation is safe!
  - Ablation success is moderate in DCM
  - ARVC-VT Ablation: Excellent Outcome
- Outflow-Tract VT
  - Recognize it! → ICDs are not indicated
  - PVCs When to intervene?
    - Symptoms
    - Ventricular Dysfunction / Dilatation
    - High burden??
- Ventricular Fibrillation
  - PVC Triggers
  - Brugada Syndrome: Substrate Ablation







MOUNT SINAL SCHOOL OF MEDICINE